story of the week
Pyrotinib Plus Capecitabine for Patients With HER2-Positive Breast Cancer and Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
Lancet Oncol 2022 Jan 24;[EPub Ahead of Print], M Yan, Q Ouyang, T Sun, L Niu, J Yang, L Li, Y Song, C Hao, Z Chen, A Orlandi, N Ishii, K Takabe, G Franceschini, F Ricci, C Verschraegen, Z Liu, M Zhang, H Lv, L Liu, X Yang, H Xiao, Z Gao, X Li, F Dong, X Chen, J Qiao, G ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.